Revolution Medicines is trading at $190.46 — up 28% over the past month and now within touching distance of the Street's mean price target — creating a fresh question about whether the re-rating has run its course or still has legs.
The most notable Street development this week is Mizuho raising its target to $215 from $185 on July 6, while keeping an Outperform rating. That move, alongside Wedbush lifting to $181 on July 2, continues the pattern of upward revisions that has defined the past five weeks. The mean consensus target now sits at $198.91, just 4.4% above the current price — a gap that has narrowed sharply as the stock has moved faster than analyst pencils. The cluster of targets from Needham ($235), Truist ($210), and Evercore ISI ($220) implies there is still room to run if daraxonrasib's Phase 3 data continues to impress. Bernstein remains the lone dissenter, sitting at Market Perform with a $151 target — a view that looks increasingly isolated. The bull case rests on a potential $10.9 billion addressable market for a pan-RAS inhibitor; the bear case flags the cloud over ERAS-0015, which has shown inferior safety relative to daraxonrasib, raising questions about pipeline depth beyond the lead asset.
Options positioning has shifted meaningfully in the bulls' direction. The put/call ratio has dropped to 0.54, well below its 20-day average of 0.70. That contrasts sharply with the first half of June, when the PCR was consistently running above 1.0 — hedging demand dominated then, and it no longer does. The z-score of -0.62 confirms the shift is real but not extreme, suggesting call-side interest has rebuilt steadily rather than spiked. Next earnings are due August 7, and the options market is not yet loading up on downside protection.
Short positioning tells a broadly neutral story. SI runs at 6.4% of the free float — meaningful, but not extreme for a clinical-stage biotech — and has actually eased 4.3% over the week, with the daily estimate pulling back from a brief spike above 13 million shares on July 1. Borrow costs have fallen sharply, down 28% on the week to 0.36%, the lowest level in the 30-day window. Availability is loose at roughly 1,958% — far above the 52-week minimum of around 1,018% — meaning the lending market presents no friction for new short positions. There is no squeeze dynamic here. The ORTEX short score of 43 is unremarkable, sitting right at the midpoint of the range.
Institutional ownership is broadly supportive. BlackRock added 2.3 million shares in the quarter ending June 30, bringing its stake to 5.3% of shares outstanding. FMR (Fidelity) added 502,000 shares through the same period. Farallon Capital remains the largest holder at 6.4%, unchanged. Adage Capital built a meaningful new position, adding over 3.2 million shares. The insider side is more cautious: CFO Jack Anders sold a small tranche at $170.32 on June 24, and independent director Sushil Patel sold approximately $850,000 of stock across multiple tranches on June 29, close to the then-current market price. Both are modest in scale — trade significance scores are low — but the direction of travel is worth noting as the stock approaches its consensus target.
The last two earnings events produced a 5.1% one-day gain in June 2026 and a 6.1% one-day decline in May 2026, so the reaction skew is genuinely two-sided. With Q2 results set for August 7, the setup to watch is whether analyst targets migrate higher again in the weeks ahead — or whether the stock's proximity to consensus mean creates a natural ceiling until the next data readout.
See the live data behind this article on ORTEX.
Open RVMD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
